Synaptogenix Inc (SNPX)

[SF Wolf]

McMagyar, investing in Neurotrope is all about the science.
The company was created and capitalized based on the research of Dr. Alkon and his team.

I have yet to read any post on this board that can refute the underlying assumptions of Dr. Alkon’s research. Other detractors, such as Adam Feuerstien at The Street, while skeptical, never address the data. So here are three statements for any would be critics that question the science to challenge:

--Dr. Alkon has spent a good part of his career at the NIH and at BRNI demonstrating the relationship between the decrease in synaptic density and the progression of Alzheimer’s disease. Can that relationship be disproved?

-- Dr. Alkon has established that increasing protein kinase C epsilon (PKCe) in the brain encourages synaptic regeneration. Any proof to the contrary?

--Dr. Alkon has shown in animal models and in Compassionate Use patients that Bryostatin-1 in activating PCKe and promoting synaptic growth can treat/reverse Alzheimer’s symptoms. Any cogent arguments to the contrary?